- Effect of CYP3A5* 3 genotype on exposure and efficacy of quetiapine: A retrospective, cohort study
- Effects of immunorelated gene polymorphisms on trastuzumab targeting breast cancer cell in vitro
- Genetic determinants of antidepressant and antipsychotic drug response
- Dopamine Transporter and CYP2D6 Gene Relationships with Attention-Deficit/Hyperactivity Disorder Treatment Response in the Methylphenidate and Atomoxetine Crossover Study
- Associations between methamphetamine use disorder and SLC18A1, SLC18A2, BDNF, and FAAH gene sequence variants and expression levels
- Pre-Emptive Pharmacogenetic Testing in the Acute Hospital Setting: A Cross-Sectional Study
- DPYD Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, American College of Medical Genetics and Genomics, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, Pharmacogenomics Knowledgebase, and Pharmacogene Variation Consortium
- CYP2C19 genotype and sodium channel blockers in lacosamide-treated children with epilepsy: two major determinants of trough lacosamide concentration or clinical response
- CXCR7 Genetic Variant Predicts Treatment Response of Pegylated-Interferon α in HBeAg-Positive Chronic Hepatitis B Patients
- Relationship between PPARG rs2290449 and the efficacy of combination therapy in sepsis with MODS in Yanbian area
Close